ALK and lung adenocarcinoma: Multiple genetic alterations have been identified as therapeutic targets in lung adenocarcinoma, including mutations in EGFR, ERBB2, BRAF, KRAS, and MET and rearrangements of ALK, RET, and ROS1 [4,5,7,8].